Mandolin has raised $40 million to enhance its AI-driven platform aimed at simplifying the access to specialty drugs, which are essential for treating severe health conditions. The funding includes support from prominent investors and industry leaders. Specialty drug expenditure is surging, with projections estimating costs to reach $1.5 trillion by 2032, complicating access due to cumbersome insurance and administrative processes. Mandolin’s solution automates these tasks, significantly reducing the time healthcare providers need to secure necessary drug approvals, thereby improving patient access and optimizing revenue flow.
Mandolin aims to revolutionize specialty drug access through AI, addressing complex administrative hurdles and helping providers save time and increase efficiency.
The platform's automation capabilities could reduce the weeks spent on administrative tasks to mere minutes, enhancing revenue flow for providers.
Collection
[
|
...
]